Wuxi Fortune Pharmaceutical has secured FDA approval for its generic Mycophenolate Mofetil (ANDA 214079), signals an escalation in its U.S. market presence. The approval will likely bolster the company's profitability while intensifying competitive pressure in the oral immunosuppressants sector.